Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Concentra Group Holdings Parent (CON)

Concentra CMO Dr. John Anderson to retire December 31, 2026; search for successor begins

Neutral Impact 3 of 5 leadership Written later

Concentra Group Holdings Parent, Inc. said Executive Vice President and Chief Medical Officer Dr. John Anderson will retire effective December 31, 2026. The company has started a formal search for his successor and expects to enter a consulting agreement with him to support the transition. The filing includes no financial results or guidance.

Key points

  • Dr. John Anderson notified the company of his retirement on April 10, 2026, effective December 31, 2026.
  • The company has initiated a formal search for Anderson's successor.
  • The company expects to enter a Consulting Agreement with Anderson to support the transition of his responsibilities.
  • Anderson joined Concentra in 1993 and has served as Chief Medical Officer since 2014.

The filing

CompanyConcentra Group Holdings Parent (CON)
Form8-K, current report
Filed with the SECApr 14, 2026, 4:46 PM ET
Accession number0001104659-26-043229

Items reported: 5.02 Director / Officer Change7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:05 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 14, 2026.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.